Mary Alpaugh

Associate Professor

    • 1484 Citations
    • 17 h-Index
    19942019

    Research output per year

    If you made any changes in Pure these will be visible here soon.

    Personal profile

    Research interests

    Research Expertise:
    Cancer Biology | Tumor Progression | Metastasis | Intravasation

    My research focuses predominantly on the molecular mechanisms of intravasation, the rate-limiting step of metastasis, and resistance/susceptibility of lymphovascular emboli to therapeutics.

    Metastasis poses the single most difficult clinical challenge in the attempt to manage and treat cancer. In this effort, I have established patient-derived xenografts, signifcantly the first (and only) human transplantable inflammatory breast cancer xenograft, called MARY-X. Inflammatory breast cancer (IBC) is one of the most aggressive types of breast cancer; nearly 100% of all women with IBC have lymph node involvement and 25% have distant metastases upon diagnosis. The signature phenotype of IBC is florid lymphovascular invasion of cancer emboli. Whereas most human xenografts grow as a subcutaneous confluent cellular mass, MARY-X grows exclusively in the murine lymphatic and blood vessels, recapitulating the phenotype displayed in human IBC and in essence providing both a preclinical IBC model and a relevant model of metastasis. MARY-X, in vitro, is a primary cellular derivative from tumor explants. These tumor cells spontaneously form tight, compact aggregates of cells termed “MARY-X spheroids”. Comparable to human IBC emboli, a persistent, over-expression of an intact E-cadherin/α, β-catenin axis mediates the compaction of both in vitro and in vivo MARY-X spheroids and tumor emboli, respectively. The in vitro MARY-X spheroid has comparative 3-dimensional (3-D) architectural/pathophysiological features to the lymphovascular embolus. Therefore MARY-X provides a relevant 3D in vitro analysis platform for drug design and development of IBC and metastatic disease i.e. the lymphovascular embolus.

    Member of:
    American Association for Cancer Research

    Education/Academic qualification

    doctorate, University of Houston

    Bachelor

    Fingerprint Dive into the research topics where Mary Alpaugh is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 1 Similar Profiles

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Projects

    Research Output

    • 1484 Citations
    • 17 h-Index
    • 29 Article
    • 1 Comment/debate
    • 1 Letter
    • 1 Review article
  • 1 Scopus citations

    Paradigms for Precision Medicine in Epichaperome Cancer Therapy

    Alpaugh, M. L., Nov 11 2019, In : Cancer Cell. 36, 5, p. 559-573.e7

    Rowan University

    Research output: Contribution to journalArticle

  • 3 Scopus citations

    Reply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’

    Alpaugh, M. L., Oct 1 2019, In : Nature genetics. 51, 10, p. 1427-1428 2 p.

    Rowan University

    Research output: Contribution to journalLetter

  • 3 Scopus citations
  • 6 Scopus citations

    Press / Media